Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

London pre-open: Stocks seen up ahead of busy week

(Sharecast News) - London stocks were set to rise at the open on Monday ahead of a busy week. The FTSE 100 was called to open around 30 points higher at 7,508.

Investors were eyeing the release of UK unemployment figures on Tuesday, while on Wednesday and Thursday, the latest US inflation data and a rate announcement by the European Central Bank are due.

Data released earlier by China's National Bureau of Statistics showed that headline consumer price inflation ticked up 0.1% in August from a year earlier following a 0.3% decline in July. Core inflation - which excludes food and fuel prices - was unchanged at 0.8%.

Pantheon Macroeconomics said: "The uptick this month was largely driven by a smaller drag from energy prices - a negative contribution of 0.1pp versus 0.4pp in July - thanks to rising oil prices recently and a more favourable carryover effect.

"Petrol prices fell at a much slower pace at 4.9% versus a fall of 13.5% in the previous month."

In UK corporate news, Vistry said it planned to merge its housebuilding operations with its partnerships business by the end of the year as it set new medium-term earnings targets.

The UK home builder said it was now aiming for return on capital employed of 40%, revenue growth of 5-8% a year and operating profit of £800m with an operating margin of at least 12%.

Vistry posted an 8.4% fall in adjusted half-year pre-tax profits to £174m amid a tough housing market where prices have been falling in response to higher mortgage costs.

Elsewhere, GSK announced that Japanese regulators are reviewing its proposed new momelotnib treatment for people with myelofibrosis - a type of blood cancer.

Momelotnib, which is currently not approved in any market, is hoped to address the significant medical needs of myelofibrosis patients, especially those with anaemia. The new drug application, which included data from clinical trials addressing key clinical manifestations of myelofibrosis, has now been accepted for review by Japan's Ministry of Health, Labour and Welfare.

Share this article

Related Sharecast Articles

London midday: FTSE touch firmer after jobs data, Pill comments
(Sharecast News) - London stocks were still just a touch firmer by midday on Tuesday as investors mulled the latest jobs data and comments from Bank of England chief economist Huw Pill.
London open: Stocks nudge up as investors mull jobs data
(Sharecast News) - London stocks were just a touch higher in early trade on Tuesday as investors mulled conflicting UK jobs data.
London pre-open: Stocks seen down as investors mull jobs data
(Sharecast News) - London stocks were set to edge lower at the open on Tuesday as investors mulled data showing the UK jobs market is cooling.
London close: Stocks take a breather after last week's surge
(Sharecast News) - London's stock markets ended the day in negative territory on Monday, with investors taking a breather following a six-day winning streak that propelled the FTSE 100 to a new all-time high.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.